A cutting-edge mouse study reveals that tirzepatide, the dual GLP-1/GIP drug already hailed for impressive weight loss, does more than trim fat: it slashes the growth of obesity-linked breast tumors.

The fat that you can see and that you can pinch between your fingers is subcutaneous fat, a layer of fat just under the skin.